ERBB2 and neoplasm: We have previously shown that fatty acid oxidation inhibitor, etomoxir, pre-emptively blocked metabolic dependencies of residual tumors and prolonged tumor dormancy in a HER-2–driven genetically engineered mouse model of dormancy (20).